Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00030056 · ClinicalTrials.gov registry record · Phase 2
GM-CSF in Patients With Pulmonary Alveolar Proteinosis
A Phase 2 study, sponsored by The Cleveland Clinic.
- Terminated
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT00030056 is a Phase 2 study that was terminated before completion, run by The Cleveland Clinic. The registered enrollment target is 48 participants.
The verdict
NCT00030056, a Phase 2 study, was terminated before completion, sponsored by The Cleveland Clinic.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
This is a study to determine the efficacy and safety of granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered subcutaneously to patients with pulmonary alveolar proteinosis (PAP).
Interventions
- DRUG GM-CSF (granulocyte-macrophage colony-stimulating factor, sargramostim)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2001-09 |
| Est. Completion | 2005-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00030056
The ClinicalTrials.gov registry entry for NCT00030056 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GM-CSF (granulocyte-macrophage colony-stimulating factor, sargramostim) is the first listed.
NCT00030056 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00030056 about?
NCT00030056 is a clinical study titled "GM-CSF in Patients With Pulmonary Alveolar Proteinosis". This is a study to determine the efficacy and safety of granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered subcutaneously to patients with pulmonary alveolar proteinosis (PAP).
What is the current status of trial NCT00030056?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2001-09. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00030056?
The interventions under investigation include: GM-CSF (granulocyte-macrophage colony-stimulating factor, sargramostim) (DRUG).
Who is sponsoring clinical trial NCT00030056?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.